Developer docs
API playgroundTry for free, no card

Search company profiles

Laguna Diagnostics

Full company profile

uuid00wopre

Namestring
Laguna Diagnostics
Legal namestring
Laguna Diagnostics, LLC
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Laguna Diagnostics is a pre-revenue medical diagnostics company developing blood-based mRNA biomarker tests to objectively distinguish between schizophrenia and bipolar I disorder in patients presenting with overlapping psychiatric symptoms. The company's lead product, the mRNA Gene Biomarker Test, is a single blood-based diagnostic that demonstrated 96.7% sensitivity for schizophrenia, 100% specificity for bipolar I disorder, and 98.3% overall accuracy in pivotal study data. The company is headquartered in Irvine, California, is structured as an LLC, and is operating in a pre-commercial development phase.

The test addresses an unmet need: current clinical diagnostic methods for these conditions rely on subjective assessment and exhibit misdiagnosis rates exceeding 50%, with diagnostic timelines of 1-3+ years. Laguna Diagnostics received FDA Breakthrough Device Designation in April 2026 and is advancing through further clinical validation studies under the Breakthrough Device program.

Once FDA clearance is obtained, the company plans to commercialize through an enterprise field sales motion targeting psychiatrists and mental health clinicians as the primary customer, with healthcare systems and psychiatric hospitals as secondary channel customers. Revenue mechanics are expected to involve one-time payments per diagnostic test sold to providers. The company is currently seeking additional funding for ongoing clinical validation and development, and no pricing, commercial partnerships, named customers, or distribution channels have been disclosed.

Short descriptiontext

Laguna Diagnostics is a pre-revenue medical diagnostics company developing a blood-based mRNA biomarker test to objectively differentiate schizophrenia from bipolar I disorder for psychiatrists and healthcare systems.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
psychiatric diagnostics, mRNA biomarker testing, differential diagnosis, blood-based diagnostics, schizophrenia screening
Industry3 codes
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Psychiatric Molecular Diagnostics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Test Sales
TypeOne Time License
Description

Pre-revenue company. Once FDA clearance is obtained, the company plans to commercialize its mRNA gene biomarker blood test. Revenue model likely to involve sale of diagnostic tests to healthcare providers, hospitals, and psychiatric practices. The company is currently seeking funding for additional development and clinical validation studies.

prnewswire.com
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Laguna Diagnostics develops a blood-based mRNA gene biomarker test designed to aid clinicians in differentiating between schizophrenia and bipolar I disorder. In pivotal studies, the test demonstrated 96.7% sensitivity for schizophrenia, 100% specificity for bipolar I disorder, and 98.3% overall accuracy. The company is pre-commercial and advancing through the FDA Breakthrough Device program with continued clinical validation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 96.7% sensitivity for schizophrenia detection
+2 more records
Product overview1 text field

Laguna Diagnostics offers a single diagnostic product: the mRNA Gene Biomarker Test. This is a blood-based test that analyzes mRNA gene biomarkers to aid clinicians in differentiating between schizophrenia and bipolar I disorder, addressing the significant diagnostic challenge where current methods show misdiagnosis rates exceeding 50% and timelines of 1-3+ years.

Product and service1 record
1mRNA Gene Biomarker Test
CategoryPsychiatric Molecular Diagnostics
Description

A blood-based diagnostic test that analyzes mRNA gene biomarkers to help clinicians differentiate between schizophrenia and bipolar I disorder in patients presenting with overlapping psychiatric symptoms. Demonstrated 96.7% sensitivity for schizophrenia, 100% specificity for bipolar I disorder, and 98.3% overall accuracy in pivotal studies. Intended for use by psychiatrists, mental health clinicians, healthcare systems, and psychiatric facilities.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Laguna Diagnostics

Psychiatric Molecular Diagnosticslagunadiagnostics.com

Laguna Diagnostics is a pre-revenue medical diagnostics company developing a blood-based mRNA biomarker test to objectively differentiate schizophrenia from bipolar I disorder for psychiatrists and healthcare systems.

What Laguna Diagnostics does

Laguna Diagnostics is a pre-revenue medical diagnostics company developing blood-based mRNA biomarker tests to objectively distinguish between schizophrenia and bipolar I disorder in patients presenting with overlapping psychiatric symptoms. The company's lead product, the mRNA Gene Biomarker Test, is a single blood-based diagnostic that demonstrated 96.7% sensitivity for schizophrenia, 100% specificity for bipolar I disorder, and 98.3% overall accuracy in pivotal study data. The company is headquartered in Irvine, California, is structured as an LLC, and is operating in a pre-commercial development phase.

The test addresses an unmet need: current clinical diagnostic methods for these conditions rely on subjective assessment and exhibit misdiagnosis rates exceeding 50%, with diagnostic timelines of 1-3+ years. Laguna Diagnostics received FDA Breakthrough Device Designation in April 2026 and is advancing through further clinical validation studies under the Breakthrough Device program.

Once FDA clearance is obtained, the company plans to commercialize through an enterprise field sales motion targeting psychiatrists and mental health clinicians as the primary customer, with healthcare systems and psychiatric hospitals as secondary channel customers. Revenue mechanics are expected to involve one-time payments per diagnostic test sold to providers. The company is currently seeking additional funding for ongoing clinical validation and development, and no pricing, commercial partnerships, named customers, or distribution channels have been disclosed.

Laguna Diagnostics firmographics

Firmographics
Name
Laguna Diagnostics
Legal name
Laguna Diagnostics, LLC
Website
https://lagunadiagnostics.com
Company type
Private
Operating status
Operating
Short description
Laguna Diagnostics is a pre-revenue medical diagnostics company developing a blood-based mRNA biomarker test to objectively differentiate schizophrenia from bipolar I disorder for psychiatrists and healthcare systems.
Ownership category
akta.pro rank

Laguna Diagnostics industry classification

Industry
Product category
Psychiatric Molecular Diagnostics
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Psychiatric diagnostics
  • MRNA biomarker testing
  • Differential diagnosis
  • Blood-based diagnostics
  • Schizophrenia screening

Where Laguna Diagnostics is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Markets served

Laguna Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Test Sales: Pre-revenue company. Once FDA clearance is obtained, the company plans to commercialize its mRNA gene biomarker blood test. Revenue model likely to involve sale of diagnostic tests to healthcare providers, hospitals, and psychiatric practices. The company is currently seeking funding for additional development and clinical validation studies.

Go-to-market motion1 record

Laguna Diagnostics product offering

Product offering

Core offering

Laguna Diagnostics develops a blood-based mRNA gene biomarker test designed to aid clinicians in differentiating between schizophrenia and bipolar I disorder. In pivotal studies, the test demonstrated 96.7% sensitivity for schizophrenia, 100% specificity for bipolar I disorder, and 98.3% overall accuracy. The company is pre-commercial and advancing through the FDA Breakthrough Device program with continued clinical validation.

Product overview

Laguna Diagnostics offers a single diagnostic product: the mRNA Gene Biomarker Test. This is a blood-based test that analyzes mRNA gene biomarkers to aid clinicians in differentiating between schizophrenia and bipolar I disorder, addressing the significant diagnostic challenge where current methods show misdiagnosis rates exceeding 50% and timelines of 1-3+ years.

Differentiator

Problem solved

Functional benefit

Products and services

  • mRNA Gene Biomarker Test A blood-based diagnostic test that analyzes mRNA gene biomarkers to help clinicians differentiate between schizophrenia and bipolar I disorder in patients presenting with overlapping psychiatric symptoms. Demonstrated 96.7% sensitivity for schizophrenia, 100% specificity for bipolar I disorder, and 98.3% overall accuracy in pivotal studies. Intended for use by psychiatrists, mental health clinicians, healthcare systems, and psychiatric facilities.

Quantifiable outcome

  • 96.7% sensitivity for schizophrenia detection
  • +2 more outcomes

Companies that use Laguna Diagnostics

Customer profile

Segments2 records

Ideal customer profiles2 records

Laguna Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Laguna Diagnostics partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves3 records

Expansion highlights3 records

Laguna Diagnostics competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key highlights5 records

Customer concentration

Laguna Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Laguna Diagnostics leadership team

Management profile

Number of profiles

Laguna Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Laguna Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laguna Diagnostics

What does Laguna Diagnostics do?

Laguna Diagnostics develops a blood-based mRNA gene biomarker test designed to aid clinicians in differentiating between schizophrenia and bipolar I disorder. In pivotal studies, the test demonstrated 96.7% sensitivity for schizophrenia, 100% specificity for bipolar I disorder, and 98.3% overall accuracy. The company is pre-commercial and advancing through the FDA Breakthrough Device program with continued clinical validation.

Is Laguna Diagnostics a public or private company?

Laguna Diagnostics is a private company. It is classified as unknown and is currently operating.

When was Laguna Diagnostics founded?

Laguna Diagnostics was founded in -1.

Where is Laguna Diagnostics based?

Laguna Diagnostics is headquartered in Irvine, United States, in the North America region.

How does Laguna Diagnostics make money?

One revenue line is on record: diagnostic Test Sales.

Does Laguna Diagnostics have an API?

No public API is recorded for Laguna Diagnostics.

What industry is Laguna Diagnostics in?

Laguna Diagnostics's product category is Psychiatric Molecular Diagnostics. Its primary akta.pro industry code is HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR), with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Clinical Lab ProductsFDA Grants Breakthrough Status to Blood Test to Distinguish Schizophrenia and Bipolar DisorderThe FDA granted Breakthrough Device Designation to Laguna Diagnostics for an mRNA gene biomarker blood test designed to help clinicians distinguish between schizophrenia and bipolar I disorder. The test demonstrated 96.7% sensitivity for schizophrenia and 100% specificity for bipolar I disorder in submitted data, with an overall accuracy of 98.3%. The company is moving through further clinical validation studies and seeking funding for additional development as the test aims to address current diagnostic timelines of one to three years that rely on subjective assessments.PR NewswireU.S. FDA Grants Breakthrough Device Designation to Laguna Diagnostics' mRNA Gene Biomarker Test to Aid in Differentiation of Schizophrenia and Bipolar I DisorderLaguna Diagnostics, LLC announced that the U.S. Food and Drug Administration granted Breakthrough Device Designation for the company's mRNA Gene Biomarker Test designed to aid in differentiating schizophrenia and bipolar I disorder. The pivotal study demonstrated 96.7% sensitivity for schizophrenia, 100% specificity for bipolar I disorder, and 98.3% overall accuracy, with current diagnostic methods showing misdiagnosis rates exceeding 50% and timelines of 1-3+ years. The company is advancing through further clinical validation studies with continued FDA engagement under the Breakthrough Device program.PR NewswireLaguna Diagnostics Announces Publication of Peer-Reviewed Study in Molecular NeuropsychiatryLaguna Diagnostics announced publication of a peer-reviewed study in Molecular Neuropsychiatry on blood-based biomarker tests for diagnosing schizophrenia and bipolar disorder, achieving 83-88% accuracy across two clinical visits using 18-gene biomarker panels with mRNA gene expression signatures. The study enrolled 90 subjects at the University of Iowa and was funded by the National Institute of Mental Health through its Small Business Innovation Research program. Validation studies with replication are still required before the tests can gain FDA approval or clinical utility.